Skip to main content
Back
Watch Compare

Foghorn Therapeutics Inc.

Data quality: 100%
FHTX
Nasdaq Manufacturing Chemicals
$4.59
▼ $0.20 (-4.18%)
Mkt Cap: 284.70 M
Price
$4.85
Mkt Cap
284.70 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Revenue grew 120.02% annually over 5 years — strong growth
Negative free cash flow of -86.15 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 83.27%
Capital efficient — spends only 0.16% of revenue on capex

Growth

Revenue Growth (5Y)
120.02%
Above sector avg (1.82%)
Revenue (1Y)36.75%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROIC-50.87%
Net Margin-240.33%
Op. Margin-279.49%

Safety

Debt / Equity
N/A
Current Ratio2.16
Interest CoverageN/A

Valuation

PE (TTM)
-3.83
Below sector avg (-1.48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -3.8 -1.5
P/B — 1.6
ROE % — -53.5
Net Margin % -240.3 -41.5
Rev Growth 5Y % 120.0 1.8
D/E — 0.3

Analyst Price Target

9 analysts
Buy
Current
$4.59
+149.3%
Target
$11.44
$9.00
$12.00
$14.00
Forecast
Forward P/E -5.04
Forward EPS -$0.91
Est. Revenue 44.22 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$0.91
-$1.19 – -$0.70
 44.22 M 7
FY2026 -$1.13
-$1.54 – -$0.79
 33.00 M 5

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$0.26 -$0.37 -42.4%
Q32025 -$0.30 -$0.25 +16.7%
Q22025 -$0.32 -$0.28 +12.0%
Q12025 -$0.29 -$0.30 -3.5%

ETFs Holding This Stock

CNCR CNCR
0.92% weight
BRSIX BRSIX
0.12% weight
GSIOX GSIOX
0.02% weight
GSTOX GSTOX
0.02% weight
GSZPX GSZPX
0.02% weight
GINUX GINUX
0.02% weight
GSROX GSROX
0.02% weight
GSCOX GSCOX
0.02% weight
WSMGX WSMGX
0.01% weight
DTSGX DTSGX
0.01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 36.75% Revenue Growth (3Y) -4.87%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 120.02% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 30.91 M Net Income (TTM) -74.28 M
ROE N/A ROA -34.45%
Gross Margin N/A Operating Margin -279.49%
Net Margin -240.33% Free Cash Flow (TTM) -86.15 M
ROIC -50.87% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2.16
Interest Coverage N/A Asset Turnover 0.14
Working Capital 99.03 M Tangible Book Value -89.66 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3.83 Forward P/E N/A
P/B Ratio N/A P/S Ratio 9.21
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -30.26%
Market Cap 284.70 M Enterprise Value 195.36 M
Per Share
EPS (Diluted TTM) -1.18 Revenue / Share 0.53
FCF / Share -1.47 OCF / Share -1.47
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.16% FCF Conversion 115.97%
SBC-Adj. FCF -97.33 M Growth Momentum -83.27

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 30.91 M 22.60 M 34.16 M 19.23 M 1.32 M
Net Income -74.28 M -86.62 M -98.43 M -108.88 M -101.32 M
EPS (Diluted) -1.18 -1.58 -2.34 -2.62 -2.73
Gross Profit — — — — —
Operating Income -86.39 M -102.68 M -107.91 M -117.14 M -100.73 M
EBITDA — — — — —
R&D Expenses 85.47 M 94.53 M 109.69 M 105.62 M 80.33 M
SG&A Expenses — — — — —
D&A 3.33 M 3.12 M 3.45 M 3.32 M 3.23 M
Interest Expense — — — — 1.91 M
Income Tax 0.0 0.0 4.23 M — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 198.10 M 283.98 M 285.92 M 404.88 M 519.77 M
Total Liabilities 306.60 M 329.51 M 363.11 M 404.77 M 422.90 M
Shareholders' Equity -108.50 M -45.53 M -77.19 M 112,000.0 96.87 M
Total Debt — — — — 0.0
Cash & Equivalents 80.88 M 55.45 M 80.34 M 52.21 M 101.14 M
Current Assets 163.24 M 249.60 M 240.18 M 351.40 M 459.56 M
Current Liabilities 59.74 M 66.99 M 58.44 M 55.21 M 48.69 M